Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

Pharmaceuticals announced that the company will present five abstracts featuring new clinical and real-world outcomes with ...

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...

A real-world cohort of patients with metastatic pancreatic adenocarcinoma (mPDAC) demonstrated that prophylaxis therapy to alleviate toxic effects was ...

A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of ...

The Clinical Guidelines Committee of the American College of Physicians (ACP) has released a new clinical guideline on the ...

Background: To systematically review and assess the in vivo effectiveness and safety of probiotics for prophylaxis and treating oral candidiasis. Methods: A literature search for studies published ...

Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...

The antibody targets a stable part of the bird flu virus, ensuring that the immune protection can resist new variants and offer long-term protection against the globally spreading airborne infection.

Orchard Therapeutics, a Kyowa Kirin company, today announced presentations from seven abstracts from across its hematopoietic stem cell (HSC) gene therapy portfolio will be featured at the 21st Annual ...